This information collection helps
support implementation of statutory and regulatory requirements
under the Public Health Service Act (PHS) and the Federal Food,
Drug, and Cosmetic Act (FD&C Act) that govern biologics product
licensing. Respondents to the information collection are biologic
product sponsors.
US Code:
21
USC 356b Name of Law: FFDCA
US Code: 42
USC 262 Name of Law: PHS Act; Regulation of Biological
Products
Form FDA 2252, Form FDA 2253, Form FDA 2252, FDA 356h, FDA
3988, FDA 3989, FDA 3674
TRANSMITTAL OF ANNUAL REPORTS FOR DRUGS AND BIOLOGICS FOR HUMAN
USE , TRANSMITTAL OF ADVERTISEMENTS AND PROMOTIONAL LABELING
FOR DRUGS AND BIOLOGICS FOR HUMAN USE , TRANSMITTAL OF
ANNUAL REPORTS FOR DRUGS AND BIOLOGICS FOR HUMAN USE ,
Transmittal of PMR/PMC Submissions for Drugs and Biological
Products , PMR/PMC Annual Status Report for Drugs and
Biological Products , Certification of Compliance ,
Application to Market a New Drug or Abbreviated New Drug or
Biologic for Human Use
We have revised the information
collection to add agency guidance and we have made nominal
adjustments in burden as enumerated in Question-12a. The result is
an increase of 9 responses and 27 hours annually to the information
collection.
$20,830,410
No
No
No
No
No
No
No
Domini Bean 301 796-5733
domini.bean@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.